← All news

TürkiyeResearch and clinical trials

Primary hyperoxaluria in 88 children from 15 centers in Türkiye: kidney loss is common when diagnosis is late

Peer-reviewed publication

A study published in a journal and reviewed by independent scientists. Even so, a single study is not conclusive; it needs to be replicated.

In Türkiye, pediatric kidney doctors studied children with primary hyperoxaluria in a national registry. The study included 88 children from 15 centers. In type 1, the median age at diagnosis was 2.6 years, and diagnosis was delayed by about 2 years. About half of the children had kidney failure at the time of diagnosis. During follow-up, more than half of the children started dialysis; the death rate was 27.7%.

What does it mean for patients and families?

Early diagnosis is very important in this disease. This disease should be considered in a child with kidney stones or calcium deposits in the kidney. Treatment and transplant decisions are made by a specialist team.

Source

PubMed (Pediatric Transplantation): Clinical Characteristics, Genetic Spectrum, and Treatment Outcomes in Children With Primary Hyperoxaluria: Results From a National Turkish Registry.

Scientific paper: Clinical Characteristics, Genetic Spectrum, and Treatment Outcomes in Children With Primary Hyperoxaluria: Results From a National Turkish Registry. Pediatric Transplantation, 2026. DOI: 10.1111/petr.70401 · PubMed 42446045

The source page was opened and read on October 7, 2026. Summary prepared by the Doktorclub editorial team and translated from Turkish; it has not yet been reviewed by a physician (a scientific board is being set up).

This page is translated from the Turkish original.

This page reports a development; it is not a treatment recommendation. Your doctor decides whether a treatment is right for you.

The information on these pages is for general information only and does not replace medical advice. Talk to your doctor about diagnosis and treatment decisions. In an emergency in Türkiye, call 112.

Every update is based on an open source and labeled with its level of evidence. No advertising and no drug brand names. Our scientific principles

This page was translated from Turkish by the Doktorclub editorial team.